Historical review from 2026-11-14. Current price and availability are unconfirmed; check the original marketplace.
Stacker is a verified iPhone app in the health and fitness niche targeting the growing peptide-tracking market. The financials show exceptionally high margins (~98%) on $445/mo revenue, with a 2.86x annual profit multiple that sits at the lower end of reasonable for a mobile app. At $15,000 asking price, the absolute dollar commitment is modest, though the small revenue base ($437/mo profit) means any customer churn would have an outsized impact. The business age is not disclosed, which limits confidence in earnings durability, but the platform verification status adds meaningful credibility to the reported figures.
A solo founder with AI coding tools (Cursor, Claude, Xcode templates) and a SwiftUI framework could reproduce the core peptide-tracking MVP — dose logging, reminders, protocol progress — in roughly 4–8 weeks at an estimated $2,000–$5,500 out-of-pocket (AI subscription, Apple Developer account, backend hosting, push notification service). The software itself is not a strong moat. However, the buy verdict is supported — narrowly — by the verified revenue, the niche App Store presence, and the modest $15K price tag that includes an operational customer base. Building from scratch would require re-acquiring App Store rankings, reviews, and an existing paying audience, which carries meaningful execution risk relative to the low acquisition cost. Missing user count and retention data prevent a higher confidence score, so buyers should request those metrics before closing.
Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.
Helps users build personalized peptide stacks, log doses, get reminders, and track protocol progress and results in one iPhone app.
Opens the original listing on TrustMRR
Get new listings with asking prices, monthly profit, deal scores, and key risks.
The best reviewed deals, concise and evidence-first. Unsubscribe anytime.
Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.